Literature DB >> 35925268

[Treatment of early and locally advanced stages of non-small cell lung cancer].

Marcel Wiesweg1,2, Wilfried E Eberhardt3,4, Martin Schuler3,4, Till Plönes5.   

Abstract

Treatment concepts for patients with localized and locally advanced non-small cell lung cancer (NSCLC) are based on local treatment, surgery and/or radiotherapy, with curative intent. An adjuvant systemic treatment is added after primary resection of an operable NSCLC primarily to reduce the systemic risk of relapse. Locally advanced stages with mediastinal lymph node involvement carry a substantial risk of local and distant recurrence and require multimodal treatment strategies in an interdisciplinary approach. Recently, immunotherapy with programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) checkpoint inhibitors is increasingly being integrated into adjuvant, neoadjuvant or perioperative treatment concepts.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Chemotherapy, adjuvant; Combined modality therapy; Immune checkpoint inhibitors; Immunotherapy, preoperative; Radiotherapy, adjuvant

Mesh:

Year:  2022        PMID: 35925268     DOI: 10.1007/s00108-022-01366-0

Source DB:  PubMed          Journal:  Inn Med (Heidelb)        ISSN: 2731-7080


  25 in total

1.  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Authors:  Patrick M Forde; Jamie E Chaft; Kellie N Smith; Valsamo Anagnostou; Tricia R Cottrell; Matthew D Hellmann; Marianna Zahurak; Stephen C Yang; David R Jones; Stephen Broderick; Richard J Battafarano; Moises J Velez; Natasha Rekhtman; Zachary Olah; Jarushka Naidoo; Kristen A Marrone; Franco Verde; Haidan Guo; Jiajia Zhang; Justina X Caushi; Hok Yee Chan; John-William Sidhom; Robert B Scharpf; James White; Edward Gabrielson; Hao Wang; Gary L Rosner; Valerie Rusch; Jedd D Wolchok; Taha Merghoub; Janis M Taube; Victor E Velculescu; Suzanne L Topalian; Julie R Brahmer; Drew M Pardoll
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation.

Authors:  Jean-Yves Douillard; Hélène Tribodet; Delphine Aubert; Frances A Shepherd; Rafael Rosell; Keyue Ding; Anne-Sophie Veillard; Lesley Seymour; Thierry Le Chevalier; Stephen Spiro; Richard Stephens; Jean Pierre Pignon
Journal:  J Thorac Oncol       Date:  2010-02       Impact factor: 15.609

3.  Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.

Authors:  Enriqueta Felip; Nasser Altorki; Caicun Zhou; Tibor Csőszi; Ihor Vynnychenko; Oleksandr Goloborodko; Alexander Luft; Andrey Akopov; Alex Martinez-Marti; Hirotsugu Kenmotsu; Yuh-Min Chen; Antonio Chella; Shunichi Sugawara; David Voong; Fan Wu; Jing Yi; Yu Deng; Mark McCleland; Elizabeth Bennett; Barbara Gitlitz; Heather Wakelee
Journal:  Lancet       Date:  2021-09-20       Impact factor: 79.321

4.  Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

Authors:  Patrick M Forde; Jonathan Spicer; Shun Lu; Mariano Provencio; Tetsuya Mitsudomi; Mark M Awad; Enriqueta Felip; Stephen R Broderick; Julie R Brahmer; Scott J Swanson; Keith Kerr; Changli Wang; Tudor-Eliade Ciuleanu; Gene B Saylors; Fumihiro Tanaka; Hiroyuki Ito; Ke-Neng Chen; Moishe Liberman; Everett E Vokes; Janis M Taube; Cecile Dorange; Junliang Cai; Joseph Fiore; Anthony Jarkowski; David Balli; Mark Sausen; Dimple Pandya; Christophe Y Calvet; Nicolas Girard
Journal:  N Engl J Med       Date:  2022-04-11       Impact factor: 176.079

5.  A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.

Authors:  Fabrice Barlesi; Christos Chouaid; Jacky Crequit; Hervé Le Caer; Jean-Louis Pujol; Julien Legodec; Alain Vergnenegre; Jacques Le Treut; Elizabeth Fabre-Guillevin; Anderson Loundou; Pascal Auquier; Marie-Claude Simeoni; Pascal A Thomas
Journal:  Interact Cardiovasc Thorac Surg       Date:  2015-03-11

6.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takayasu Kurata; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Corinne Faivre-Finn; Martin Reck; Johan Vansteenkiste; David R Spigel; Catherine Wadsworth; Giovanni Melillo; Maria Taboada; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

7.  Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.

Authors:  Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox
Journal:  Lancet       Date:  2009-07-24       Impact factor: 79.321

8.  Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.

Authors:  Jean-Yves Douillard; Rafael Rosell; Mario De Lena; Marcello Riggi; Patrick Hurteloup; Marc-Andre Mahe
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-24       Impact factor: 7.038

9.  Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).

Authors:  Wilfried Ernst Erich Eberhardt; Christoph Pöttgen; Thomas Christoph Gauler; Godehard Friedel; Stefanie Veit; Vanessa Heinrich; Stefan Welter; Wilfried Budach; Werner Spengler; Martin Kimmich; Berthold Fischer; Heinz Schmidberger; Dirk De Ruysscher; Claus Belka; Sebastian Cordes; Rodrigo Hepp; Diana Lütke-Brintrup; Nils Lehmann; Martin Schuler; Karl-Heinz Jöckel; Georgios Stamatis; Martin Stuschke
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

10.  Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.

Authors:  John V Heymach; Boris Sepesi; Tina Cascone; William N William; Annikka Weissferdt; Cheuk H Leung; Heather Y Lin; Apar Pataer; Myrna C B Godoy; Brett W Carter; Lorenzo Federico; Alexandre Reuben; Md Abdul Wadud Khan; Hitoshi Dejima; Alejandro Francisco-Cruz; Edwin R Parra; Luisa M Solis; Junya Fujimoto; Hai T Tran; Neda Kalhor; Frank V Fossella; Frank E Mott; Anne S Tsao; George Blumenschein; Xiuning Le; Jianjun Zhang; Ferdinandos Skoulidis; Jonathan M Kurie; Mehmet Altan; Charles Lu; Bonnie S Glisson; Lauren Averett Byers; Yasir Y Elamin; Reza J Mehran; David C Rice; Garrett L Walsh; Wayne L Hofstetter; Jack A Roth; Mara B Antonoff; Humam Kadara; Cara Haymaker; Chantale Bernatchez; Nadim J Ajami; Robert R Jenq; Padmanee Sharma; James P Allison; Andrew Futreal; Jennifer A Wargo; Ignacio I Wistuba; Stephen G Swisher; J Jack Lee; Don L Gibbons; Ara A Vaporciyan
Journal:  Nat Med       Date:  2021-02-18       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.